SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: Investigating Marrow Infiltrating Lymphocytes as a Source of Adoptive Cellular Therapy in Renal Cell Carcinoma and Urothelial Carcinoma

Investigating Marrow Infiltrating Lymphocytes as a Source of Adoptive Cellular Therapy in Renal Cell Carcinoma and Urothelial Carcinoma

  • Org Study ID: OU-SCC-WindMIL-001
  • Secondary ID:
  • NCT ID: NCT04341740
  • NCT Alias:
  • Sponsor: University of Oklahoma - Other
  • Source: University of Oklahoma

Brief Summary

The purpose of this research is to collect health-related information as well as bone marrow and blood specimens to determine if a new form of treatment for patients with kidney and bladder cancer may be possible.

Detailed Description

This research will collect specimens from the bone marrow and blood to determine if a new
treatment for kidney or bladder cancer may be possible. This research study will collect a
bone marrow sample as well as a blood sample.

Participation in the research study will last approximately 60 days which includes time to
determine if the patient is eligible to participate in the study, perform the research
procedures and follow-up with the patient following the research procedures to determine if
they are experiencing any side effects. Participation will end approximately 30 days
following the bone marrow collection.

Overal Status Start Date Phase Study Type
Recruiting July 2020 Early Phase 1 Interventional

Primary Outcomes:

Primary Outcome 1 - Measure: Proportion of subjects with successful isolation and ex-vivo expansion of MILs

Primary Outcome 1 - Time Frame: 30 days


  • Renal Cell Carcinoma
  • Urothelial Carcinoma


Inclusion Criteria:

- Age ≥18 years

- Histologically-confirmed, locally advanced unresectable or metastatic RCC (cohort A)
or UC (cohort B).

- ECOG performance status of ≤1

- Adequate bone marrow function:

- Platelet count ≥ 100 × 10^9/L

- ANC ≥ 1.0 ×10^9/L

- Lymphocyte count ≥ 1.0 ×10^9/L

- Willingness to undergo bone marrow aspiration (BMA)

Exclusion Criteria:

- Prior hematopoietic stem cell transplantation

- Prior radiation to the pelvic region

- Use of systemic corticosteroids within 28 days of BMA

- History of another primary malignancy that has been diagnosed or required therapy
within the past 2 years (except completely resected basal cell and squamous cell skin
cancer, curatively treated localized prostate cancer, and completely resected
carcinoma in situ of any site).

- Presence of an autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis,
systemic lupus erythematosis) requiring active systemic treatment. If the autoimmune
disease has been treated, it must be stable clinically. (Hypothyroidism without
evidence of Grave's disease or Hashimoto's thyroiditis is not considered an exclusion

- Pregnant females as documented by a serum beta human chorionic gonadotropin (β-hCG)
pregnancy test consistent with pregnancy, obtained within 21 days of BMA

- Infection requiring treatment with antibiotics, antifungal, or antiviral agents within
7 days of BMA

- Known diagnosis of HIV or CMV infection or active viral hepatitis

- Administration of hematopoietic growth factor support within 14 days before bone
marrow aspiration

- Chemotherapy administration within 28 days of BMA

- Unwilling or unable to comply with the protocol

- Prior or ongoing clinically significant illness, medical condition, surgical history,
physical finding, or laboratory abnormality that, in the Investigator's opinion, could
affect the safety of the subject.
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: Abhishek Tripathi, MD

Role: Principal Investigator

Affiliation: University of Oklahoma

Overall Contact

Name: Lead GU Nurse

Phone: 1-405-271-8777



Facility Status Contact
Stephenson Cancer Center
Oklahoma City, Oklahoma 73104
United States
Recruiting Ingrid Block, APRN